NMDA receptors and schizophrenia.
The pathophysiology of schizophrenia is poorly understood but is likely to involve alterations in excitatory glutamatergic signaling molecules in several areas of the brain. Clinical and experimental evidence has shown that expression of the N-methyl-D-aspartate (NMDA) receptor and intracellular NMDA receptor-interacting proteins of the glutaminergic synapse appear to be dysregulated in schizophrenia. It has been suggested that schizophrenia involves molecular changes in the glutamatergic pathways that mediate excitatory communication between multiple brain regions. Recent data also implicate abnormalities in cellular functions such as receptor trafficking and synaptic targeting.
Kristiansen
Lars V
LV
University of Alabama at Birmingham, Department of Psychiatry and Behavioral Neurobiology, SC560, 1530 3rd Avenue South, Birmingham, AL 35294-0017, USA. larsk@uab.edu
Huerta
Ibone
I
Beneyto
Monica
M
Meador-Woodruff
James H
JH
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use; D006801:Humans; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism*
D014150:Antipsychotic Agents; D016194:Receptors, N-Methyl-D-Aspartate